Infobuttons for Genomic Medicine: Requirements and Barriers.


Journal

Applied clinical informatics
ISSN: 1869-0327
Titre abrégé: Appl Clin Inform
Pays: Germany
ID NLM: 101537732

Informations de publication

Date de publication:
03 2021
Historique:
entrez: 12 5 2021
pubmed: 13 5 2021
medline: 3 11 2021
Statut: ppublish

Résumé

The study aimed to understand potential barriers to the adoption of health information technology projects that are released as free and open source software (FOSS). We conducted a survey of research consortia participants engaged in genomic medicine implementation to assess perceived institutional barriers to the adoption of three systems: ClinGen electronic health record (EHR) Toolkit, DocUBuild, and MyResults.org. The survey included eight barriers from the Consolidated Framework for Implementation Research (CFIR), with additional barriers identified from a qualitative analysis of open-ended responses. We analyzed responses from 24 research consortia participants from 18 institutions. In total, 14 categories of perceived barriers were evaluated, which were consistent with other observed barriers to FOSS adoption. The most frequent perceived barriers included lack of adaptability of the system, lack of institutional priority to implement, lack of trialability, lack of advantage of alternative systems, and complexity. In addition to understanding potential barriers, we recommend some strategies to address them (where possible), including considerations for genomic medicine. Overall, FOSS developers need to ensure systems are easy to trial and implement and need to clearly articulate benefits of their systems, especially when alternatives exist. Institutional champions will remain a critical component to prioritizing genomic medicine projects.

Identifiants

pubmed: 33979874
doi: 10.1055/s-0041-1729164
pmc: PMC8116174
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

383-390

Subventions

Organisme : NHGRI NIH HHS
ID : U01 HG008676
Pays : United States
Organisme : NHGRI NIH HHS
ID : U01 HG008657
Pays : United States
Organisme : NHGRI NIH HHS
ID : U01 HG006382
Pays : United States
Organisme : NHGRI NIH HHS
ID : U01 HG008672
Pays : United States
Organisme : NHGRI NIH HHS
ID : U01 HG008684
Pays : United States
Organisme : NHGRI NIH HHS
ID : U01 HG008679
Pays : United States
Organisme : NHGRI NIH HHS
ID : U01 HG008666
Pays : United States
Organisme : NIMHD NIH HHS
ID : U54 MD007593
Pays : United States
Organisme : NHGRI NIH HHS
ID : U01 HG008680
Pays : United States
Organisme : NHGRI NIH HHS
ID : U01 HG008673
Pays : United States
Organisme : NHGRI NIH HHS
ID : U01 HG008685
Pays : United States
Organisme : NHGRI NIH HHS
ID : U01 HG006379
Pays : United States
Organisme : NHGRI NIH HHS
ID : U01 HG008664
Pays : United States
Organisme : NHGRI NIH HHS
ID : U01 HG008701
Pays : United States

Informations de copyright

Thieme. All rights reserved.

Déclaration de conflit d'intérêts

L.V.R. reports grants from NIH/NHGRI during the conduct of the study and also has a Provisional Patent related to the design of Ancillary Genomic Systems that is no longer being pursued. J.B.S. reports a grant from NIH/NHGRI 1U01 HG008673–01 during the conduct of the study and also has a provisional patent related to the design of Ancillary Genomic Systems that is no longer being pursued. R.R.F. reports grants from NIH/NHGRI during the conduct of the study.

Références

Proc AMIA Annu Fall Symp. 1997;:528-32
pubmed: 9357682
Genet Med. 2021 Apr;23(4):603-605
pubmed: 33299147
N Engl J Med. 2015 Jun 4;372(23):2235-42
pubmed: 26014595
Appl Clin Inform. 2012 Dec 12;3(4):462-74
pubmed: 23646091
J Pathol Inform. 2015 Sep 28;6:50
pubmed: 26605115
Int J Technol Assess Health Care. 2017 Jan;33(4):487-493
pubmed: 28857016
F1000Res. 2017 Mar 15;6:273
pubmed: 28443186
J Am Med Inform Assoc. 2013 Jun;20(e1):e9-e13
pubmed: 23599226
Nucleic Acids Res. 2018 Jan 4;46(D1):D1062-D1067
pubmed: 29165669
J Am Med Inform Assoc. 2016 Sep;23(5):899-908
pubmed: 26911829
Yearb Med Inform. 2017 Aug;26(1):53-58
pubmed: 28480476
Implement Sci. 2009 Aug 07;4:50
pubmed: 19664226
Stud Health Technol Inform. 2013;192:672-6
pubmed: 23920641
Int J Med Inform. 2013 May;82(5):e73-86
pubmed: 23146626
Appl Clin Inform. 2016 Aug 31;7(3):817-31
pubmed: 27579472
Methods Inf Med. 2018 Dec;57(S 02):e115-e123
pubmed: 30605914
Appl Clin Inform. 2016 Sep 21;7(3):870-82
pubmed: 27652374

Auteurs

Luke V Rasmussen (LV)

Department of Preventive Medicine, Northwestern University, Chicago, Illinois, United Sates.

John J Connolly (JJ)

The Center for Applied Genomics, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United Sates.

Guilherme Del Fiol (G)

Department of Biomedical Informatics, University of Utah, Salt Lake City, Utah, United Sates.

Robert R Freimuth (RR)

Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, United Sates.

Douglas B Pet (DB)

Department of Neurology, University of California San Francisco, San Francisco, California, United Sates.

Josh F Peterson (JF)

Department of Biomedical Informatics, Vanderbilt University School of Medicine, Nashville, Tennessee, United Sates.

Brian H Shirts (BH)

Department of Laboratory Medicine, University of Washington, Seattle, Washington, United Sates.

Justin B Starren (JB)

Department of Preventive Medicine, Northwestern University, Chicago, Illinois, United Sates.

Marc S Williams (MS)

Genomic Medicine Institute, Geisinger, Danville, Pennsylvania, United Sates.

Nephi Walton (N)

Genomic Medicine Institute, Geisinger, Danville, Pennsylvania, United Sates.
Intermountain Precision Genomics, Intermountain Healthcare, St George, Utah, United Sates.

Casey Overby Taylor (CO)

Genomic Medicine Institute, Geisinger, Danville, Pennsylvania, United Sates.
Department of Medicine and Biomedical Engineering, Johns Hopkins School of Medicine, Baltimore, Maryland, United Sates.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH